Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
May 14, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
May 13, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024Company to Host Key Opinion Leader Webinar on the Potential of Briquilimab in...
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
May 07, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
March 21, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
March 19, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
March 15, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
Three additional patients with Fanconi Anemia treated with briquilimab prior to stem cell transplantAll six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and...
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
March 04, 2024 07:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
February 26, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 23, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...